To explore the clinical relevance of IP-10, we examined the expression levels of IP-10 in an independent cohort of 48 patients diagnosed with PDAC, in which mRNA microarray analysis of tumor tissues was performed and published by Dozynkiewicz and colleagues [23]. The gene discussed is CXCL10; the disease is neoplasm.